Kits for labeling of biomarkers and methods of using the same

Patent metadata

Field	Value
Publication number	US-10871485-B2
Application number	US-201916383227-A
Country	US
Kind code	B2
Filing date	Apr 12, 2019
Priority date	Apr 13, 2018
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

Kits, compositions, and methods for labeling target materials or target analytes are considered. The composition can include one or more affinity molecules indirectly conjugated to one or more detection moieties. The kit can be used to detect a single biomarker or multiple biomarkers. The kit can be used to perform a single round of labeling or multiple rounds of labeling.

First claim

What is claimed is:

1. A kit comprising:
a first affinity molecule-first oligonucleotide conjugate;
a horseradish peroxidase (“HRP”) molecule-second oligonucleotide conjugate; and
a tyramide-first detection moiety conjugate,
wherein the first and second oligonucleotides are complementary, and
wherein the tyramide and the first detection moiety are conjugated via complementary third and fourth oligonucleotides.

2. The kit of claim 1 , further comprising at least one signal disrupter to de-hybridize or cleave the third and fourth oligonucleotides.

3. The kit of claim 1 , further comprising at least one signal disrupter to eliminate or reduce a signal capable of being provided by the first detection moiety.

4. The kit of claim 1 , further comprising:
a second affinity molecule-third oligonucleotide conjugate;
a horseradish peroxidase (“HRP”) molecule-fourth oligonucleotide conjugate;
a tyramide-second detection moiety conjugate,
wherein the third oligonucleotide of the second affinity molecule-third oligonucleotide conjugate and the fourth oligonucleotide of the HRP molecule-fourth oligonucleotide conjugate are complementary.

5. The kit of claim 4 , wherein the first and second affinity molecules are directed to different biomarkers.

6. The kit of claim 4 , wherein the first and second detection moieties have different emission wavelengths.

7. The kit of claim 4 , further comprising at least one signal disrupter to de-hybridize or cleave at least one of the first and second oligonucleotides or the third oligonucleotide of the second affinity molecule-third oligonucleotide conjugate and the fourth oligonucleotide of the HRP molecule-fourth oligonucleotide conjugate.

8. The kit of claim 4 , further comprising at least one signal disrupter to eliminate or reduce a signal capable of being provided by at least one of the first and second detection moieties.

9. A kit comprising:
a first affinity molecule-first oligonucleotide conjugate;
a horseradish peroxidase (“HRP”) molecule-second oligonucleotide conjugate;
a tyramide-first detection moiety conjugate,
a second affinity molecule-third oligonucleotide conjugate;
a HRP molecule-fourth oligonucleotide conjugate; and
a tyramide-second detection moiety conjugate,
wherein the first and second oligonucleotides are complementary,
wherein the third and fourth oligonucleotides are complementary,
wherein the tyramide and the first detection moiety of the tyramide-first detection moiety conjugate are conjugated via complementary fifth and sixth oligonucleotides; and
wherein the tyramide and the second detection moiety of the tyramide-second detection moiety conjugate are conjugated via complementary seventh and eighth oligonucleotides.

10. The kit of claim 9 , further comprising at least one signal disrupter to de-hybridize or cleave one or more of the oligonucleotide pairs.

11. A method for labeling a target analyte of a sample, the method comprising:
adding, to the sample, a first affinity molecule-first oligonucleotide conjugate;
adding, to the sample, a horseradish peroxidase (“HRP”) molecule-second oligonucleotide conjugate; and
adding, to the sample, a tyramide-first detection moiety conjugate,
wherein the first and second oligonucleotides are complementary and hybridize with each other, and
wherein the tyramide and the first detection moiety are conjugated via complementary third and fourth oligonucleotides.

12. The method of claim 11 , wherein the tyramide-first detection moiety conjugate is added after the first affinity molecule-first oligonucleotide conjugate and the HRP-second oligonucleotide.

13. The method of claim 11 , wherein the tyramide-first detection moiety conjugate is conjugated before the step of adding the tyramide-first detection moiety conjugate.

14. The method of claim 11 , wherein the step of adding the tyramide-first detection moiety conjugate further comprises the steps of:
adding, to the sample, a tyramide-third oligonucleotide conjugate; and
adding, to the sample, a fourth oligonucleotide-first detection moiety conjugate.

15. The method of claim 11 , further comprising the steps of:
observing a first signal of the first detection moiety; and
modifying the first signal with a signal disrupter,
wherein the observing the first signal and modifying the first signal steps are performed after the adding steps.

16. The method of claim 15 , wherein the signal disrupter de-hybridizes the third and fourth oligonucleotides.

17. The method of claim 11 , further comprising:
adding, to the sample, a second affinity molecule-third oligonucleotide conjugate;
adding, to the sample, a horseradish peroxidase (“HRP”) molecule-fourth oligonucleotide conjugate; and
adding, to the sample, a tyramide-second detection moiety conjugate,
wherein the third and fourth oligonucleotides are complementary.

18. The method of claim 17 , wherein the first and second affinity molecules are directed to different biomarkers.

19. The method of claim 17 , wherein the first and second detection moieties have different emission wavelengths.

20. The method of claim 17 , further comprising the steps of:
observing a first signal of the first detection moiety; and
modifying the first signal with a signal disrupter.

21. The method of claim 20 , further comprising the step of observing a second signal of the second detection moiety, wherein the first and second signals have the same emission wavelength, and wherein the observing and modifying steps for the first signal of the first detection moiety are performed before adding the tyramide-second detection moiety conjugate.

22. A method for labeling a target analyte of a sample, the method comprising:
adding, to the sample, a first affinity molecule-first oligonucleotide conjugate;
adding, to the sample, a horseradish peroxidase (“HRP”) molecule-second oligonucleotide conjugate;
adding, to the sample, a tyramide-first detection moiety conjugate,
adding, to the sample, a second affinity molecule-third oligonucleotide conjugate;
adding, to the sample, a HRP molecule-fourth oligonucleotide conjugate; and
adding, to the sample, a tyramide-second detection moiety conjugate,
wherein the first and second oligonucleotides are complementary,
wherein the third and fourth oligonucleotides are complementary,
wherein the tyramide and the first detection moiety of the tyramide-first detection moiety conjugate are conjugated via complementary fifth and sixth oligonucleotides; and
wherein the tyramide and the second detection moiety of the tyramide-second detection moiety conjugate are conjugated via complementary seventh and eighth oligonucleotides.

Assignees

• Rarecyte Inc

Inventors

• Campton Daniel E
• Sun Yao

Classifications

• G01N33/582 Primary

  with fluorescent label · CPC title

• G01N33/588

  with semiconductor nanocrystal label, e.g. quantum dots · CPC title

• G01N33/581

  with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates) · CPC title

• C12Q1/6804

  Nucleic acid analysis using immunogens (immunoassay G01N33/53) · CPC title

• G01N2800/70

  Mechanisms involved in disease identification (G01N2800/02 - G01N2800/44 take precedence) · CPC title